Aethlon Medical Inc (AEMD) Quote

https://www.otcmarkets.com/stock/AEMD

https://www.otcmarkets.com/stock/AEMD

https://www.otcmarkets.com/stock/AEMD

AEMD new 52 week low

AEMD new 52 week low

https://www.otcmarkets.com/stock/AEMD

HAS AMED R/S YET ?????

AEMD
Aethlon Medical Inc
0.331
-0.0156 (-4.50%)
Volume: 77,709
Day Range: 0.3213 - 0.3466
Last Trade Time: 7:52:36 PM EDT

Ahhh the ole R/S to purge the investors. I kissed this one goodbye a long time ago. This will be my 3rd R/S. Nothing left of this garbage I've had stinkin up my portfolio since 2014. This is what they do in pennyland. Per the proxy: Reverse stock split of our common stock at a ratio in the range of 1-for-8 to 1-for-12, with such ratio to be determined in the discretion of our Board of Directors and with such reverse stock split to be effected at such time and date as determined by our Board of Directors in its sole discretion.

AEMD
Aethlon Medical Inc
0.436
0.0016 (0.37%)
Volume: 87,927
Day Range: 0.4201 - 0.4599
Bid: 0.4359
Ask: 0.4499
Last Trade Time: 7:30:44 PM EDT
Total Trades: 258

Gathering steam. Yes, $AEMD$

yes AEMD
Aethlon Medical Inc
0.4344
-0.0159 (-3.53%)
Volume: 217,584
Day Range: 0.432 - 0.46
Bid: 0.4562
Ask: 0.458
Last Trade Time: 4:36:56 PM EDT
Total Trades: 384

Stairway to heaven!!

AEMD
Aethlon Medical Inc
0.418
-0.007 (-1.65%)
Volume: 761,142
Day Range: 0.40 - 0.4375
Last Trade Time: 7:54:26 PM EDT

AEMD
Aethlon Medical Inc
0.418
-0.007 (-1.65%)
Volume: 761,142
Day Range: 0.40 - 0.4375
Bid: 0.417
Ask: 0.4349
Last Trade Time: 7:54:26 PM EDT
Total Trades: 1,490

close .425 according to my fidlelity.
bought a few more a tad higher than close. Nice volume. Glad though I added a few days ago as well.

yes, creeping <> AEMD
Aethlon Medical Inc
0.4101
0.0701 (20.62%)
Volume: 8,100,795
Day Range: 0.38 - 0.50
Bid: 0.4101
Ask: 0.417
Last Trade Time: 7:58:04 PM EDT
Total Trades: 10,320

Potential here is quite large and transformative in more than a few areas. fda seems quite cooperative now too which is quite unusual.

Jun-30-23 12:42PM
Aethlon Medical, Inc. (NASDAQ:AEMD) Q4 2023 Earnings Call Transcript
(Insider Monkey)
-9.82%
Jun-28-23 04:15PM
Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update
(PR Newswire)
+7.85%
Jun-22-23 08:01AM
Aethlon Medical to Release Fourth Quarter and Year End Financial Results and Host Conference Call on June 28, 2023
(PR Newswire)
Jun-21-23 08:01AM
Aethlon Medical Announces Investigation of the Hemopurifier® for Use in Organ Transplantation
(PR Newswire)
Jun-14-23 08:01AM
Aethlon Medical to Participate in the Healthcare Virtual Conference Presented by Maxim Group and Hosted by M-Vest
(PR Newswire)
09:13AM
Loading…
Jun-08-23 09:13AM
AEMD: Maximizing R&D Spending to Facilitate Clinical Efforts, Advance Hemopurifier
(Zacks Small Cap Research)
Jun-01-23 03:51PM
Aethlon Medical to Present at the 13th Annual LD Micro Invitational
(PR Newswire)

https://finance.yahoo.com/news/aethlon-medical-inc-nasdaq-aemd-164226202.html

https://finance.yahoo.com/news/aethlon-medical-inc-nasdaq-aemd-164226202.html

Book/sh 0.75

Market Cap 8.28M

Aethlon Medical to Release Fourth Quarter and Year End Financial Results and Host Conference Call on June 28, 2023 • PR Newswire (US) • 06/22/2023 12:01:00 PM

Short Interest 0.10M

Shs Float 22.70M

Shs Outstand 22.95M

https://finviz.com/quote.ashx?t=AEMD&ty=c&ta=1&p=d

NEUTRAL <> interesting yet ????? $AEMD 06-18-2020 Aethlon Announces FDA Approval of IDE Supplement for COVID-19 Patients
PR Newswire PR Newswire•June 18, 2020
Allows for enrollment of up to 40 subjects in up to 20 centers

https://finance.yahoo.com/news/aethlon-announces-fda-approval-ide-131900535.html

SAN DIEGO, June 18, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the U.S. Food and Drug Administration (FDA) has approved a

supplement to the Company's existing Investigational Device Exemption (IDE) for the Company's Hemopurifier® in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19 in a new feasibility study.

The feasibility study, which is the device equivalent of a phase 1 trial, will enroll up to 40 subjects at up to 20 centers in the U.S. Subjects will have established laboratory diagnosis of COVID-19,

be admitted to an intensive care unit (ICU) and will have acute lung injury and/or severe or life threatening disease among other criteria.

The Hemopurifier has previously been tested in patients with hepatitis
C virus (HCV) infection and in one patient with Ebola virus infection.

A laboratory version of the Hemopurifier has also been shown to clear multiple other viruses in vitro including a model version of the
Middle Eastern Respiratory Syndrome (MERS) virus which is a
coronavirus from the same family as the SARS-CoV-2 virus that causes COVID-19.

Timothy C. Rodell, M.D., Chief Executive Officer of Aethlon, stated,
"We believe that the Hemopurifier may have the potential to help severely affected patients with COVID-19.

We believe that clearing circulating virus in these patients, in combination with other supportive measures, could improve outcomes in this deadly disease."

The Hemopurifier is an FDA designated "Breakthrough Device" for the treatment of life-threatening viruses that are not addressed with approved therapies.

The Hemopurifier also holds a Breakthrough Device designation for the treatment of individuals with advanced or metastatic cancer who are

either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease.

About Aethlon Medical, Inc.
Aethlon Medical, Inc. is focused on addressing unmet needs in global health.

The Aethlon Hemopurifier is a clinical-stage device designed to combat cancer and life-threatening viral infections.

Aethlon also owns 80% of Exosome Sciences, Inc., which is focused on
the discovery of exosomal biomarkers to diagnose and monitor cancer
and neurological disease progression. Additional information can be found online at
http://www.AethlonMedical.com and http://www.ExosomeSciences.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially," "appear" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, Aethlon Medical, Inc.'s (the Company) ability to enroll patients and to successfully complete the Early Feasibility Studies in viral diseases and cancer and achieve the endpoints for the study or any future studies with its Hemopurifier or to successfully develop and commercialize the Hemopurifier. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2019, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Continue reading

http://ih.advfn.com/stock-market/NASDAQ/aethlon-medical-AEMD/stock-news/82687431/aethlon-announces-fda-approval-of-ide-supplement


Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 x3300
Jfrakes@aethlonmedical.com

Media Contact:
Tony Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650

Cision
Cision
More
View original content:http://www.prnewswire.com/news-releases/aethlon-announces-fda-approval-of-ide-supplement--for-covid-19-patients-301079557.html

NEUTRAL <> interesting yet ????? $AEMD 06-18-2020 Aethlon Announces FDA Approval of IDE Supplement for COVID-19 Patients
PR Newswire PR Newswire•June 18, 2020
Allows for enrollment of up to 40 subjects in up to 20 centers

https://finance.yahoo.com/news/aethlon-announces-fda-approval-ide-131900535.html

SAN DIEGO, June 18, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the U.S. Food and Drug Administration (FDA) has approved a

supplement to the Company's existing Investigational Device Exemption (IDE) for the Company's Hemopurifier® in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19 in a new feasibility study.

The feasibility study, which is the device equivalent of a phase 1 trial, will enroll up to 40 subjects at up to 20 centers in the U.S. Subjects will have established laboratory diagnosis of COVID-19,

be admitted to an intensive care unit (ICU) and will have acute lung injury and/or severe or life threatening disease among other criteria.

The Hemopurifier has previously been tested in patients with hepatitis
C virus (HCV) infection and in one patient with Ebola virus infection.

A laboratory version of the Hemopurifier has also been shown to clear multiple other viruses in vitro including a model version of the
Middle Eastern Respiratory Syndrome (MERS) virus which is a
coronavirus from the same family as the SARS-CoV-2 virus that causes COVID-19.

Timothy C. Rodell, M.D., Chief Executive Officer of Aethlon, stated,
"We believe that the Hemopurifier may have the potential to help severely affected patients with COVID-19.

We believe that clearing circulating virus in these patients, in combination with other supportive measures, could improve outcomes in this deadly disease."

The Hemopurifier is an FDA designated "Breakthrough Device" for the treatment of life-threatening viruses that are not addressed with approved therapies.

The Hemopurifier also holds a Breakthrough Device designation for the treatment of individuals with advanced or metastatic cancer who are

either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease.

About Aethlon Medical, Inc.
Aethlon Medical, Inc. is focused on addressing unmet needs in global health.

The Aethlon Hemopurifier is a clinical-stage device designed to combat cancer and life-threatening viral infections.

Aethlon also owns 80% of Exosome Sciences, Inc., which is focused on
the discovery of exosomal biomarkers to diagnose and monitor cancer
and neurological disease progression. Additional information can be found online at
http://www.AethlonMedical.com and http://www.ExosomeSciences.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially," "appear" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, Aethlon Medical, Inc.'s (the Company) ability to enroll patients and to successfully complete the Early Feasibility Studies in viral diseases and cancer and achieve the endpoints for the study or any future studies with its Hemopurifier or to successfully develop and commercialize the Hemopurifier. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2019, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Continue reading

http://ih.advfn.com/stock-market/NASDAQ/aethlon-medical-AEMD/stock-news/82687431/aethlon-announces-fda-approval-of-ide-supplement


Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 x3300
Jfrakes@aethlonmedical.com

Media Contact:
Tony Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650

Cision
Cision
More
View original content:http://www.prnewswire.com/news-releases/aethlon-announces-fda-approval-of-ide-supplement--for-covid-19-patients-301079557.html

good rev reading

good rev reading

Things are getting much brighter here. 14 Million in the bank and ........


Aethlon Medical Q4 EPS $(0.11) Up From $(0.25) YoY, Sales $574.25K Up From $13.12K YoY

BENZINGA

4:37 PM ET 06/28/2023
Aethlon Medical (NASDAQ:AEMD) reported quarterly losses of $(0.11) per share. This is a 56 percent increase over losses of $(0.25) per share from the same period last year. The company reported $574.25 thousand in sales this quarter. This is a 4.28K percent increase over sales of $13.12 thousand the same period last year.

AEMD
Aethlon Medical Inc
0.3772
-0.0012 (-0.32%)
Volume: 205,819
Day Range: 0.3728 - 0.38
Last Trade Time: 7:35:14 PM EDT

MAYBE CHANCE FER BIG ONE ????? $AMED

AEMD
Aethlon Medical Inc
0.3092
0.0136 (4.60%)
Volume: 133,425
Day Range: 0.300001 - 0.32
Last Trade Time: 7:10:51 PM EDT

AEMD
Aethlon Medical Inc
0.3092
0.0136 (4.60%)
Volume: 133,425
Day Range: 0.300001 - 0.32
Last Trade Time: 7:10:51 PM EDT

AEMD
Aethlon Medical Inc
0.38
-0.0168 (-4.23%)
Volume: 479,255
Day Range: 0.3601 - 0.40
Last Trade Time: 7:59:20 PM EDT

Choo choo play as they want the chase.

AEMD

mb

I can't find any major news today on AEMD, not even on their website.

IMO : ONE WORD
DUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUMPO !!
BULLSHIT PR.

AEMD
Aethlon Medical Inc
0.399899
0.020299 (5.35%)
Volume: 84,613
Day Range: 0.3798 - 0.40
Last Trade Time: 6:54:32 PM EDT

AEMD
Aethlon Medical Inc
0.5024
0.0024 (0.48%)
Volume: 101,457
Day Range: 0.49 - 0.5133
Last Trade Time: 7:19:09 PM EST

The Company recently contracted with NAMSA, LLC 2023 (NAMSA), www.namsa.com, a world-leading MedTech CRO offering global end-to-end development services, to direct our planned oncology study in Australia and the United States. This new clinical trial in oncology is planned to be a safety, feasibility and dose finding trial in solid tumors failing anti-PD-1 antibodies. We believe that this trial will help inform the design of future efficacy trials of our Hemopurifier in oncology. The Company plans to initiate this trial first in Australia and then in the United States. {very smart move to hire Dr. Arnold and commence trials in Australia first. The US fda is a toxic organization and everyone who knows anything about pharmaceuticals knows this but may not admit it in public}



We recently hired Lee Arnold, PhD, as our new Chief Scientific Officer. Dr. Arnold is a creative scientific leader with 36 years of accomplishments in molecularly-targeted drug discovery. After an initial eight publications in biophysics and biochemistry as an undergraduate at University of Waterloo, he earned a PhD in Organic Chemistry from University of Alberta. Dr. Arnold began his career in pharma research at Syntex, Inc. (Canada), and then joined Pfizer Inc., where he was the inventor of Tarceva® (erlotinib) for non-small cell lung cancer, or NSCLC. During his tenure at BASF/Abbott Bioresearch Center, he established medicinal & combinatorial chemistry operations, and initiated and led two multinational multidisciplinary projects in angiogenesis, ultimately leading to linifanib (ABT-869). As Vice President of Research at OSI Pharmaceuticals, Dr. Arnold and his teams discovered four oncology development candidates, including the “first-in-class” agents linsitinib (IGF-1R), and ASP7486 (TORC1/2).



Dr. Arnold also has served as Chief Scientific Officer (CSO) in a number of innovative start-up biotechnology companies. Just prior to joining Aethlon Medical, Dr. Arnold was the CSO and cofounder of Pardes Biosciences, Inc., which was established at the start of the COVID pandemic as a virtual company that discovered and advanced the oral protease inhibitor, pomotrelvir, into clinical trials for SARS-CoV2 in only 17 months. Dr. Arnold’s inventive and leadership contributions in drug discovery and development to date have resulted in an approved drug, and 16 additional development candidates, currently fueling eight clinical trials in oncology, immunology and virology. These achievements are documented in over 94 published patents and applications, and more than 39 peer-reviewed publications.

AEMD
Aethlon Medical Inc
0.6174
-0.0426 (-6.45%)
Volume: 634,599
Day Range: 0.5901 - 0.6899
Last Trade Time: 7:56:18 PM EST

I tried to tell you that. I can’t put my finger on how this company operates their business plan or why they bother to be on the Pinks, except to gain access to the liquidity and to me, if anything ever comes from their little filter, it’s gonna go through their related company, not this POS.

A very strange entity this one is, in my opinion.

yes, something not right Aethlon Medical Inc

Somehow I knew you would still be here pumping this garbage. As I said 2 years ago, go get a Fram oil filter at AutoZone and do the same thing, in my opinion

P.S. The market agrees with ME

plus they have plenty of cash and relatively small number of shares outstanding.

I'm a hold also. I'm looking forward to the cancer trials. They said "second half of 2023" in Australia.
For now though we need to get share price over $1.00 and stay there.